Immunome, Inc. (IMNM)
| Market Cap | 2.22B +37.9% |
| Revenue (ttm) | n/a -23.2% |
| Net Income | -282.65M |
| EPS | -2.60 |
| Shares Out | 118.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 951,064 |
| Open | 18.62 |
| Previous Close | 18.70 |
| Day's Range | 18.10 - 18.92 |
| 52-Week Range | 16.11 - 30.06 |
| Beta | 2.66 |
| Analysts | Strong Buy |
| Price Target | 35.13 (+87.16%) |
| Earnings Date | Nov 9, 2026 |
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including I... [Read more]
Financial Performance
In 2025, Immunome's revenue was $6.94 million, a decrease of -23.23% compared to the previous year's $9.04 million. Losses were -$212.39 million, -27.50% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price target is $35.13, which is an increase of 87.16% from the latest price.
News
Immunome registers to sell 4.43M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 4.43M shares of common stock. The company is not selling any…
Immunome files automatic mixed securities shelf
17:02 EST Immunome (IMNM) files automatic mixed securities shelf
Immunome price target lowered to $30 from $33 at Piper Sandler
Piper Sandler analyst Biren Amin lowered the firm’s price target on Immunome (IMNM) to $30 from $33 and keeps an Overweight rating on the shares after the company reported Q3…
Immunome price target lowered to $23 from $24 at Stifel
Stifel analyst Dara Azar lowered the firm’s price target on Immunome (IMNM) to $23 from $24 and keeps a Hold rating on the shares.
Immunome Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Varegacestat is advancing toward an FDA decision by end-April 2027, with global launch preparation underway. ADC priorities include novel-target programs and upcoming IM-1021 ROR1 data, which showed a 53% response rate in the June cut.
Immunome reports Q3 EPS (76c), consensus (60c)
“We made significant progress across our oncology pipeline in recent months,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome (IMNM). “We continue to advance varegacesta...
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced fi...
Immunome Earnings release: Q3 2026
Immunome released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Immunome Quarterly report: Q3 2026
Immunome has published its Q3 2026 quarterly earnings report on November 9, 2026.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, anno...
Immunome presents initial first-in-human data from Phase 1 study of IM-1021
Immunome (IMNM) announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate, ADC, for the tre...
Immunome presents initial first-in-human data from Phase 1 study of IM-1021
Immunome (IMNM) announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate, ADC, for the tre...
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced th...
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today ann...
Immunome announces EMA validated MAA for varegacestat
Immunome (IMNM) announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, MAA, for varegacestat, an investigational, oral, once-daily gamma secretase in...
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today ann...
Immunome presents additional clinical data for varegacestat at ESMO 2026
Immunome (IMNM) announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncol...
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today ann...
Immunome initiated with an Outperform at William Blair
William Blair initiated coverage of Immunome (IMNM) with an Outperform rating. The company is nearing its first approval with varegacestat, a gamma secretase inhibitor for desmoid tumors, and is build...
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Immunome initiated with a Hold at Stifel
Stifel analyst Dara Azar initiated coverage of Immunome (IMNM) with a Hold rating and $24 price target Varegacestat’s “debatable differentiation” on efficacy, pain and convenience and second-in-class ...
Immunome announces IND clearance for IM-1340 in solid tumors
Immunome (IMNM) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for IM-1340, a potential first-in-class antibody-drug conjugate for the treatm...
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today ann...
Immunome initiated with a Buy at Alliance Global
Alliance Global initiated coverage of Immunome (IMNM) with a Buy rating and $32 price target Immunome is a biotechnology company focused on developing therapeutics for oncology, the analyst tells inve...
Immunome Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Varegacestat has been filed with a PDUFA date, and launch preparation is prioritizing medical affairs; a retreatment study is underway. The ADC pipeline centers on ROR1 and HC74, with clinical development targeting differentiated activity and an upcoming intended ASH data presentation.